News
ROIV
35.80
-0.91%
-0.33
Analysts Have Conflicting Sentiments on These Healthcare Companies: Roivant Sciences (ROIV) and Johnson & Johnson (JNJ)
TipRanks · 16h ago
Wainwright maintains confidence in Immunovant’s pipeline despite CLE setback
TipRanks · 3d ago
Roivant's IMVT-1402 Shows Positive Trends In Lupus Skin Disease Study, But Misses Main Goal
NASDAQ · 3d ago
Immunovant Ends Autoimmune Skin Disorder Program
Benzinga · 3d ago
Roivant Sciences price target raised to $41 from $37.50 at BofA
TipRanks · 3d ago
Roivant slips as Immunovant faces trial setback for cutaneous lupus therapy
Seeking Alpha · 3d ago
Roivant announces trial of IMVT-1402 did not reach statistical significance
TipRanks · 3d ago
Roivant And Immunovant Say Topline Results From Period 1 Of Proof-of-concept Trial of IMVT-1402 (Imeroprubart) For Cutaneous Lupus Erythematosus Did Not Achieve Statistical Significance On The Primary Endpoint
Benzinga · 3d ago
Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX) and Roivant Sciences (ROIV)
TipRanks · 3d ago
Why Roivant Sciences (ROIV) Is Back In The Spotlight
Simply Wall St · 4d ago
Weekly Report: what happened at ROIV last week (0914-0918)?
Weekly Report · 5d ago
FDA, Duke-Margolis workshop to examine evidence standards for rare diseases
Seeking Alpha · 6d ago
Did Positive PH ILD Trial Data Just Shift Roivant Stock Investment Narrative?
Simply Wall St · 09/19 10:19
Roivant Shareholders Approve Directors and Governance Matters
TipRanks · 09/18 11:47
This Paymentus Holdings Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Benzinga · 09/17 11:51
Roivant Sciences Initiated at Buy by Stifel
Dow Jones · 09/17 10:34
Roivant Sciences Price Target Announced at $51.00/Share by Stifel
Dow Jones · 09/17 10:34
Stifel Initiates Coverage On Roivant Sciences with Buy Rating, Announces Price Target of $51
Benzinga · 09/17 10:24
Roivant Sciences initiated with a Buy at Stifel
TipRanks · 09/16 20:15
Leerink Partners Sticks to Their Buy Rating for Roivant Sciences (ROIV)
TipRanks · 09/16 12:55
More
Webull provides a variety of real-time ROIV stock news. You can receive the latest news about Roivant Sciences through multiple platforms. This information may help you make smarter investment decisions.
About ROIV
Roivant Sciences Ltd. is a biopharmaceutical company focused on improving the lives of patients by accelerating the development and commercialization of medicines that matter. The Company’s pipeline includes brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis and cutaneous sarcoidosis; IMVT-1402 and batoclimab, fully human monoclonal antibodies targeting FcRn in development across several IgG-mediated autoimmune indications; and mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business.